Clik here to view.
Pivotal exhibiting VASCAZEN at AHA scientific sessions
Pivotal Therapeutics (OTCQX:PVTTF; CNSX:PVO) is exhibiting at the American Heart Association’s (AHA) Scientific Sessions 2012 in Los Angeles until Nov. 7, 2012. The AHA attracts over 20,000 scientists...
View ArticleClik here to view.
Pivotal exhibiting at ACC Expo
Pivotal Therapeutics (OTCQX:PVTTF; CNSX:PVO) will exhibiting at the American College of Cardiology’s 62nd Annual Scientific Session and EXPO on Mar. 9 to 11, in San Francisco. The ACC is the largest...
View ArticleClik here to view.
Pivotal Therapeutics to present REVEAL data at ATVB
Pivotal Therapeutics (OTCQX:PVTTF; CNSX:PVO) will be presenting top-line results from its recently concluded REVEAL clinical trial at the American Heart Association’s Arteriosclerosis, Thrombosis and...
View ArticleClik here to view.
James Gandolfini’s death highlights risk factors for heart attack
The recent and widely reported death of actor James Gandolfini highlights the need to aggressively address the known risk factors for heart attack and sudden cardiac death. George Jackowski “Omega-3...
View ArticleClik here to view.
Pivotal’s VASCAZEN improves omega-3 levels
Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) has announced the publication of results of a prospective randomized controlled trial in the U.S. that evaluated the effects of VASCAZEN in the correction of...
View ArticleClik here to view.
In conversation with Pivotal Therapeutics
BioTuesdays.com recently sat down with the management team at Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to discuss the company’s VASCAZEN product that addresses Omega-3 deficiency in cardiovascular...
View ArticleIn conversation with Pivotal Therapeutics
BioTuesdays.com recently sat down with the management team at Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to discuss the company’s VASCAZEN product that addresses Omega-3 deficiency in cardiovascular...
View Article
